557 related articles for article (PubMed ID: 35488273)
1. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication.
Chen D; Liu P; Lu X; Li J; Qi D; Zang L; Lin J; Liu Y; Zhai S; Fu D; Weng Y; Li H; Shen B
J Exp Clin Cancer Res; 2024 Apr; 43(1):125. PubMed ID: 38664705
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of single-cell and bulk RNA sequencing data reveals a myeloid cell-related regulon predicting neoadjuvant immunotherapy response across cancers.
Liu H; Sima X; Xiao B; Gulizeba H; Zhao S; Zhou T; Huang Y
J Transl Med; 2024 May; 22(1):486. PubMed ID: 38773508
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L; Chen H; Yang W; Ji Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy.
Feng JL; Liang B; Zheng WJ; Xu L; Zhou QY; Chen J
Cancer Immunol Immunother; 2024 May; 73(7):121. PubMed ID: 38714579
[TBL] [Abstract][Full Text] [Related]
6. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence.
Wu Z; Uhl B; Gires O; Reichel CA
J Biomed Sci; 2023 Mar; 30(1):21. PubMed ID: 36978029
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating PD-1
Yang Z; Deng Y; Cheng J; Wei S; Luo H; Liu L
Front Oncol; 2021; 11():695006. PubMed ID: 34604032
[TBL] [Abstract][Full Text] [Related]
8. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy.
Liu C; Xie J; Lin B; Tian W; Wu Y; Xin S; Hong L; Li X; Liu L; Jin Y; Tang H; Deng X; Zou Y; Zheng S; Fang W; Cheng J; Dai X; Bao X; Zhao P
Adv Sci (Weinh); 2024 Apr; ():e2401061. PubMed ID: 38569519
[TBL] [Abstract][Full Text] [Related]
10. Systematic Analysis of Tumor Stem Cell-related Gene Characteristics to Predict the PD-L1 Immunotherapy and Prognosis of Gastric Cancer.
Wang C; Chen Y; Zhou R; Yang Y; Fang Y
Curr Med Chem; 2024; 31(17):2467-2482. PubMed ID: 37936456
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response.
Zhang W; Zhu Y; Liu H; Zhang Y; Liu H; Adegboro AA; Dang R; Dai L; Wanggou S; Li X
NPJ Precis Oncol; 2024 Mar; 8(1):77. PubMed ID: 38538696
[TBL] [Abstract][Full Text] [Related]
12. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
15. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
Takamatsu S; Hamanishi J; Brown JB; Yamaguchi K; Yamanoi K; Murakami K; Gotoh O; Mori S; Mandai M; Matsumura N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868660
[TBL] [Abstract][Full Text] [Related]
16. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
18. Integration of scRNA-seq and bulk RNA-seq constructs a stemness-related signature for predicting prognosis and immunotherapy responses in hepatocellular carcinoma.
Wang X; Chen X; Zhao M; Li G; Cai D; Yan F; Fang J
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13823-13839. PubMed ID: 37535162
[TBL] [Abstract][Full Text] [Related]
19. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
20. A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.
Yang J; Liu Q; Shyr Y
Cancer Res; 2024 Feb; 84(4):626-638. PubMed ID: 38117502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
